A phase IIa study of the anti-PD-L1 antibody avelumab in relapsed/refractory PTCL: The AVAIL-T trial.
A checkpoint antibody shows activity in rare, treatment-resistant lymphomas, extending survival possibilities for difficult cases.
Peripheral T-cell lymphomas (PTCL) are rare chemoresistant malignancies with poor outcomes, necessitating novel therapies. Intention-to-treat analysis showed an overall response rate of 14.3%, median progression-free survival of 2.8 months (95% confidence interval [CI]; 1.8-3.4) and median overall survival of 10.3 months (95% CI; 6.0-12.3).
What the study was
- Study design
- Phase II trial
- Population
- patients
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- British journal of haematology
Why it surfaced
Score 6/10 [EARLY_CANCER_DETECTION]: Phase II trial (Journal Article) matched 'Hematologic malignancies'. Components — novelty:2/3, relevance:2/3, design:1/2, population:1/2. Confidence: high. Conservative scoring applied per v1.3 rubric.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.